CHICAGO, May 13, 2024 /PRNewswire/ -- Biologics Safety
Testing Market in terms of revenue was estimated to be
worth $4.2 billion in 2024 and is
poised to reach $7.2 billion by 2029,
growing at a CAGR of 11.1% from 2024 to 2029 according to a new
report by MarketsandMarkets™.
Some factors contributing to the growth of the global market
includes increasing R&D investments fundings in
biopharmaceutical industry, growing development of biologics,
stringent regulatory requirements for biologics safety testing, and
increasing number of strategic alliances for the development of
novel therapeutics. However, ethical concern regarding animal
testing is expected to hinder market growth.
Download an Illustrative overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144
Browse in-depth TOC on "Biologics Safety Testing
Market"
435 - Tables
64 - Figures
404 -
Pages
Biologics Safety Testing Market Scope:
Report
Coverage
|
Details
|
Market Revenue in
2024
|
$4.2 billion
|
Estimated Value by
2029
|
$7.2 billion
|
Growth Rate
|
Poised to grow at a
CAGR of 11.1%
|
Market Size Available
for
|
2022–2029
|
Forecast
Period
|
2024–2029
|
Forecast
Units
|
Value (USD
Billion)
|
Report
Coverage
|
Revenue Forecast,
Competitive Landscape, Growth Factors, and Trends
|
Segments
Covered
|
Product & Service,
Test Type, Application, and End User
|
Geographies
Covered
|
North America, Europe,
Asia Pacific, Latin America, Middle East, and Africa
|
Report
Highlights
|
Updated financial
information / product portfolio of players
|
Key Market
Opportunities
|
Increasing focus on
next generation therapeutics
|
Key Market
Drivers
|
Increasing development
of mAbs and biosimilars
|
The services segment accounted for the largest share of the
product & service segment in the biologics safety testing
market in 2023.
Based on product & service, the biologics safety testing
market is segmented into services, consumables, and instrument.
Services segment is further divided into endotoxin testing
services, mycoplasma testing services, sterility testing
services, bioburden testing services, virus safety testing
services, and other testing services. Services segment dominated
the market in 2023 and is expected to dominate the market in the
forecast period. The largest share of the segment is attributed to
surge in outsourcing of biologics safety testing services by
biopharmaceutical companies.
The pharmaceutical & biotechnology companies segment is
estimated to register the highest growth rate during the forecast
period in the biologics safety testing market.
Based on end user, the biologics safety testing market is
segmented into pharmaceutical & biotechnology companies, CROs
and CDMOs, and academic and research institutes. The pharmaceutical
& biotechnology companies segment is estimated to register the
highest growth rate during the forecast period. The rising demand
for biopharmaceuticals such as vaccine and monoclonal
antibodies due to increasing incidence of chronic diseases is
anticipated to promote the growth of pharmaceutical &
biotechnology companies segment in coming years.
The Asia Pacific region is
the fastest-growing region of the biologics safety testing market
in 2023.
Based on the region, the biologics safety testing market is
segmented into six major regions: North
America, Europe,
Asia Pacific, Latin America, Middle East, and Africa. The Asia
Pacific is anticipated to register fastest growth in the
biologics safety testing market owing to the increasing focus on
development of advanced therapies such as cell and gene therapies,
high government investments & fundings for R&D, and booming
biotechnology industries.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=34624144
Biologics Safety Testing Market Dynamics:
Drivers:
- Increasing development of mAbs and biosimilars
Restraints:
- Ethical concern related to animal testing
Opportunities:
- Increasing focus on next generation therapeutics
Challenge:
- Challenges related to biologics complexity
and heterogenicity
Key Market Players of Biologics Safety Testing
Industry:
Key players in the biologics safety testing market include
Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), FUJIFILM Corporation
(Japan), Sartorius AG
(Germany), F. Hoffmann-La Roche
Ltd (Switzerland), Charles River
Laboratories (US), BIOMÉRIEUX (France), Maravai LifeSciences (US), WuXi
AppTec (China), SGS Société
Générale de Surveillance SA. (Switzerland), Sotera Health (Nelson
Laboratories, LLC) (US), Samsung Biologics (South Korea), GenScript (US), Agilent
Technologies, Inc. (US), Syngene International Limited
(India), Eurofins Scientific
(Luxembourg), Laboratory
Corporation of America Holdings (US), Bio-Rad Laboratories, Inc.
(US), QIAGEN (Netherlands),
Promega Corporation (US), Catalent, Inc (US), ASSOCIATES OF
CAPE COD, INC. (US), Pacific
BioLabs (US), Clean Biologics (France), PathoQuest (France), ARL Bio Pharma, Inc. (US), Frontage
Labs (US), Creative Biogene (US), Advaxia Biologics (Italy).
The primary interviews conducted for this report can be
categorized as follows:
- By Respondent: Supply Side- 60% and Demand Side 40%
- By Designation: Managers - 45%, CXO & Directors - 30%, and
Executives - 25%
- By Region: North America -
40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=34624144
Recent Developments of Biologics Safety Testing
Industry:
- In January 2024, Chales River
Laboratories launched Endosafe Trillium rCR cartridge, a new
animal-free testing solution for robust bacterial endotoxin
testing.
- In November 2023, Merck KGaA has
developed biosafety testing laboratories in Shanghai, China. The facility aims to enable
the clients to locally access a broad range of testing services for
cell line characterization and lot release from pre-clinical
development to commercialization.
- In March 2023, LabCorp
collaborated with Forge Biologics for gene therapy development and
manufacturing. Under this partnership gene therapy clients will
have access to drug development services, manufacturing
capabilities, scientific expertise, for adeno-associated virus
(AAV) mediated gene therapy programs.
Biologics Safety Testing Market - Key Benefits of Buying the
Report:
The report will help market leaders/new entrants by providing
the closest approximations of the revenue numbers for the overall
biologics safety testing market and its subsegments. It will also
help stakeholders better understand the competitive landscape and
gain more insights to position their business better and make
suitable go-to-market strategies. This report will enable
stakeholders to understand the market's pulse and provide them with
information on the key market drivers, restraints, opportunities,
and challenges.
The report provides insights on the following
pointers:
- Analysis of key drivers (growing development of mAbs and
biosimilars, rising investments and fundings in biopharmaceutical
industry, and stringent regulatory guidelines for biologics
safety), restraints (ethical concern regarding animal testing),
opportunities (growing opportunities in emerging economies,
increasing focus on next generation therapeutics), and Challenges
(high cost of biologics) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly
launched products of the biologics safety testing market
- Market Development: Comprehensive information about lucrative
markets - the report analyses the market across varied
regions.
- Market Diversification: Exhaustive information about new
products, untapped geographies, recent developments, and
investments in the biologics safety testing market.
- Competitive Assessment: Thermo Fisher Scientific Inc. (US),
Merck KGaA (Germany), Lonza
(Switzerland), FUJIFILM
Corporation (Japan), Sartorius AG
(Germany), F. Hoffmann-La Roche
Ltd (Switzerland), Charles River
Laboratories (US), BIOMÉRIEUX (France), Maravai LifeSciences (US), WuXi
AppTec (China), SGS Société
Générale de Surveillance SA. (Switzerland), Sotera Health (Nelson
Laboratories, LLC) (US), Samsung Biologics (South Korea), GenScript (US), Agilent
Technologies, Inc. (US), Syngene International Limited
(India), Eurofins Scientific
(Luxembourg), Laboratory
Corporation of America Holdings (US), Bio-Rad Laboratories, Inc.
(US), QIAGEN (Netherlands),
Promega Corporation (US), Catalent, Inc (US), ASSOCIATES OF
CAPE COD, INC. (US), Pacific
BioLabs (US), Clean Biologics (France), PathoQuest (France), ARL Bio Pharma, Inc. (US), Frontage
Labs (US), Creative Biogene (US), Advaxia Biologics (Italy), among others in the market.
Related Reports:
Sterility Testing Market - Global Forecasts to 2028
Single Use Bioreactors Market - Global Forecasts to
2028
Blood Screening Market - Global Forecasts to 2028
Molecular Diagnostics Market - Global Forecasts to
2028
Biological Safety Cabinet Market - Global Forecasts to
2027
Get access to the latest updates on Biologics Safety Testing
Companies and Biologics Safety Testing Market Share
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's
best management consulting firms by Forbes, as per their recent
report.
MarketsandMarkets™ is a blue ocean alternative in growth
consulting and program management, leveraging a man-machine
offering to drive supernormal growth for progressive organizations
in the B2B space. We have the widest lens on emerging technologies,
making us proficient in co-creating supernormal growth for
clients.
Earlier this year, we made a formal transformation into one of
America's best management consulting firms as per a survey
conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are
substituting existing revenue streams in this decade alone. We work
with clients on growth programs, helping them monetize this
$25 trillion opportunity through our
service lines - TAM Expansion, Go-to-Market (GTM) Strategy to
Execution, Market Share Gain, Account Enablement, and Thought
Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several
Forbes Global 2000 B2B companies - helping them stay relevant in a
disruptive ecosystem. Our insights and strategies are molded by our
industry experts, cutting-edge AI-powered Market Intelligence
Cloud, and years of research. The KnowledgeStore™ (our Market
Intelligence Cloud) integrates our research, facilitates an
analysis of interconnections through a set of applications, helping
clients look at the entire ecosystem and understand the revenue
shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us
on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish
Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo:
https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/biologics-safety-testing-market-worth-7-2-billion--marketsandmarkets-302143381.html